Respiratory syncytial virus (RSV) vaccine debut after 50 years

The New York Times, August 21, 2023: After 50 years of repeated failed attempts of discovering respiratory syncytial virus (RSV) vaccine, The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention has approved Pfizer respiratory syncytial virus (RSV) vaccine – ABRYSVO™ for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. Arexvy™, the first RSV was approved previously by rival GSK on May 3, 2023. Researchers have solved the 50-year-old-mystery by scrutinizing the shape of the proteins. A new era of vaccine development with similar approach of COVID vaccine has been discovered.